WO2008156285A1 - Procédé de production d'un pansement en mousse hydrophile et pansement en mousse hydrophile ainsi produit - Google Patents

Procédé de production d'un pansement en mousse hydrophile et pansement en mousse hydrophile ainsi produit Download PDF

Info

Publication number
WO2008156285A1
WO2008156285A1 PCT/KR2008/003414 KR2008003414W WO2008156285A1 WO 2008156285 A1 WO2008156285 A1 WO 2008156285A1 KR 2008003414 W KR2008003414 W KR 2008003414W WO 2008156285 A1 WO2008156285 A1 WO 2008156285A1
Authority
WO
WIPO (PCT)
Prior art keywords
polyurethane
polyurethane foam
foam
dressing
foam dressing
Prior art date
Application number
PCT/KR2008/003414
Other languages
English (en)
Inventor
Won Il Kim
Seoung Wan Jang
Woo Kyun Kim
Oh Hyeong Kwon
Original Assignee
Wonbiogen Co., Ltd.
Kumoh National Institute Of Technology Industry-Academic Cooperation Foundation
Lee, Hyang Lim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080018998A external-priority patent/KR100937816B1/ko
Application filed by Wonbiogen Co., Ltd., Kumoh National Institute Of Technology Industry-Academic Cooperation Foundation, Lee, Hyang Lim filed Critical Wonbiogen Co., Ltd.
Priority to CN2008800211005A priority Critical patent/CN101730515B/zh
Publication of WO2008156285A1 publication Critical patent/WO2008156285A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
    • A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F13/0283—Apparatus or processes for manufacturing adhesive dressings or bandages for making adhesive or cohesive tape or fabrics therefor, e.g. coating or mechanical treatments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
    • B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B27/00—Layered products comprising a layer of synthetic resin
    • B32B27/40—Layered products comprising a layer of synthetic resin comprising polyurethanes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B32—LAYERED PRODUCTS
    • B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
    • B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
    • B32B5/18—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by features of a layer of foamed material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00621—Plasters form or structure cast
    • A61F2013/00634—Plasters form or structure cast foam

Definitions

  • the present invention relates to a method for producing a hydrophilic foam dressing that protects injuries such as burns and/or wounds and conducive to wound healing, and a hydrophilic foam dressing produced thereby. More specifically, the present invention relates to a method for manufacturing a hydrophilic polyurethane foam dressing with remarkably improved productivity and processing efficiency, which can improve physical properties of the polyurethane foam dressing, and a hydrophilic polyurethane foam dressing produced by the same.
  • An ideal dressing must maintain a wet condition between a wound and the dressing, have favorable absorbability and moisture permeability, and prevent drying of a wound and skin festering around the wound. Furthermore, the dressing needs other properties including, for example, gas exchange and inhibition of bacterial invasion, and must not adhere to a surface of the wound and must not cause damage to granulation tissue on the wound during the dressing change. Additionally, a dressing enabling convenient observation of healing progress, and having non-stimulation, favorable availability and economic advantage may also be preferable. Research and investigations continue into development of an improved dressing that can satisfy the requirements described above. [5]
  • OpSite was introduced as a semi-transparent thin film that keeps a wound wet, facilitates lysis of necrotic tissues and formation of granulation tissues, thereby promoting wound care, tbwever, wound exudates are excessively gathered in the wounded area, causing skin festering and/or leakage of the exudates from the wound, thus, the film is inconvenient because the exudates must be occasionally removed from the wound.
  • DuoDERM was developed in the United States as a hydro-colloidal dressing, which reacts with wound exudates to provide a moist condition in a gel state when adhered to a wound and to promote epithelialization of the wound, tbwever, this dressing has disadvantages that gas such as oxygen and carbon dioxide or water vapor cannot permeate the dressing so that wound exudates are excessively gathered in the wound area and that gel may remain on the wound after the dressing change.
  • Dressings using polymers were generally manufactured by gellation but, in recent years, foam production methods have been proposed to prepare a polymer foam using, for example, polyurethane, so as to form open cells.
  • 5,147,338 disclose a polyurethane foam dressing manufactured by admixing a hydrophilic polyurethane prepolymer having at least two isocyanate terminals and a foaming agent such as water, a non-ionic surfactant and/or an antibacterial agent such as silver sulfadiazine and foaming the mixture.
  • the disclosed polyurethane foam dressing typically has a thickness of 0.5 to 20mm, permeability of 300 to 5,000g/m724hrs (at a relative hunidity of 10 to 100% at 3TC), an open cell size of 30 to 700/M, open porosity (open cell rate) of 20 to 70%, and a three-layered structure with an outer film thickness of 12.5 to 37.5/M.
  • hydrophilic polyurethane foam having a thickness of 1 to 10cm and a density of 0.16 to 0.8g/cnf.
  • This dressing is manufactured by mixing a hydrophilic material such as sodiun carboxymethylcellulose, calciun carboxymethylcellulose, pectin, gelatin, guar gun, locust bean gun, collagen, karaya gun and the like together
  • TM TM wwiitthh aann iinnssoolluubbllee hhyyddrroopphhiilliicc ppoollyymer such as Aqualon , Water Lock available from Grain Processing Corp., etc.
  • Korean Patent No. 0404140 discloses a method of producing a polyurethane foam dressing which comprises mixing a hydrophilic polyurethane prepolymer having an isocyanate terminal, a cross-linking agent, a foaming agent, an additive and the like under stirring, placing the mixture in a mold, and foaming the mixture.
  • IHbwever in order to manufacture the polyurethane foam dressing with desired different thicknesses, various types and/or forms of molds are required. Above all, the above method mostly produces the dressing in a single-sheet form with a constant size, thus having poor productivity.
  • Korean Patent No. 0553078 describes a method for manufacturing a polyurethane foam dressing which comprises pouring a hydrophilic polyurethane prepolymer, a cross-linking agent, a foaming agent, an additive and so on into a large mold, foaming the mixture in the mold to prepare a block type polyurethane foam, and removing a skin layer and cutting the foam into a certain thickness using a horizontal cutter and laminating an additional outer film layer on the cut foam.
  • the conventional method disclosed above has a limitation of adopting a mold foaming process.
  • this method requires multiple steps including, for example: mixing a hydrophilic polyurethane prepolymer having an isocyanate terminal, water as a foaming agent and other additive(s) and foaming the mixture in a frame having a certain size, thickness and/or shape to form a block type polyurethane foam; cutting the produced block type foam into pieces having a constant thickness; and combining the cut piece with an outer film layer. Therefore, the conventional method may encounter a problem of processing complexity, which in turn, results in considerably decreased productivity and processing efficiency. Moreover, when raw materials are mixed together in a mold, instant foaming occurs, leading to limited 'pot life.' As a result, the conventional method also has disadvantages in view of shape-forming processes.
  • the polyurethane foam dressing manufactured by the conventional method disclosed above typically has open cells with a large size on a skin facing side thereof, thus having high absorption rate of wound exudates, tbwever, the foam dressing may merge with skin tissues regenerated in the wound and possibly cause pain or secondary damage when the dressing is removed from the skin.
  • Patent Application Nos. 10-2005-0107898 Korean Patent No. 716658 and 10-2006-0026887, disclosing a dressing with a three-layered structure, which comprises: a non-porous polyurethane film layer to isolate a wound from ambient atmosphere; a polyurethane foam based inner absorptive layer with high absorbability, which has open cells with a size of 1 to 600/M and is located below the non-porous film layer; and a wound contact layer that does not adhere to wounds, has microfine open cells with a size of 1 to 50/M and absorbs wound exudates.
  • these patent applications proposed a dressing manufactured by a series of processes including: mixing a hydrophilic polyurethane prepolymer, water and a surfactant under stirring to prepare a foaming mixture, applying the foaming mixture to a release sheet to a certain thickness using a comma coater, foaming the coated sheet and winding the foamed sheet in a roll form, thereby accomplishing noticeably improved productivity and processing efficiency thereof.
  • an object of the present invention is to provide a simple and effective process for manufacturing a foam dressing with a three-layered structure comprising: a film layer; an inner absorptive layer; and a wound contact layer, thereby noticeably improving productivity and processing efficiency thereof.
  • Patent Application No. 10-2006-0026887 had difficulty in manufacturing products with a constant thickness with passage of time, since a foaming mixture applied to a surface of a coater cured after 2 hours in terms of production time due to a limited 'pot life.' Therefore, another object of the present invention is to solve the above problem and to provide a process for manufacturing products with a constant thickness regardless of 'pot life' even if the process is continued for a long time, thereby remarkably improving workability thereof.
  • a still further object of the present invention is to provide a polyurethane foam dressing with improved physical properties, especially, one which exhibits considerably increased absorption rate through surface modification of the foam.
  • step (b) 100 wt. parts of the polyurethane prepolymer obtained in step (b) under stirring at a high speed to prepare a foaming mixture;
  • step (e) feeding the foaming mixture obtained in step (d) to a release sheet fixed at a certain angle such that the foaming mixture flows along an inclined surface of the release sheet and becomes foam to produce a tacky gel type polyurethane foam layer before being cured to a thickness of 1 to 20mm;
  • step (f) laminating the polyurethane foam layer obtained in step (e) on the non-porous waterproof polyurethane film layer obtained in step (a) and pressing the laminate while maintaining a certain gap therebetween to regulate a thickness of the foam dressing.
  • the process of the present invention may further include a step of impregnating the polyurethane foam dressing obtained in step (f) with a moisturizer and drying the treated foam dressing and/or treating the polyurethane foam dressing with oxygen plasma, so that the foam layer has an increased absorption rate.
  • the process of the present invention may also include a step of ageing the polyurethane foam dressing in a hot air dryer after the lamination step (f).
  • the foaming composition of step (c) may additionally include 0.01 to 20 wt. parts of a drug(s).
  • a process for manufacturing a hydrophilic foam dressing comprising: impregnating a polyurethane foam dressing with a moisturizer and drying the treated foam dressing, and/or treating the polyurethane foam dressing with oxygen plasma to increase the absorption rate of the foam and a hydrophilic foam dressing manufactured by the same.
  • FIGS. 1 to 4 are schematic views illustrating polyurethane foam dressing according to the present invention
  • FIG. 5 is scanning electron microscope (SEM) photographs showing an absorptive layer and a wound contact layer of a polyurethane foam dressing according to
  • FIG. 6 is SEM photographs showing an absorptive layer and a wound contact layer of a polyurethane foam dressing according to Production Example 16 of the present invention
  • FIG. 7 is SEM photographs showing an absorptive layer and a wound contact layer of a polyurethane foam dressing according to Production Example 17 of the present invention
  • FIG. 8 is SEM photographs showing an absorptive layer and a wound contact layer of a polyurethane foam dressing according to Production Example 21 of the present invention
  • FIG. 9 is SEM photographs showing MEDIFOAM-N available from IL DONG
  • FIG. 10 is SEM photographs showing MEDIFOAM-FTM available from IL DONG
  • FIG. 11 is SEM photographs showing ALLEVYN available from SMITH &
  • FFIIGG.. 1122 iiss SEM photographs showing CAREFOAMTM available from SAERON Pharmaceutical Co., LTD.;
  • FIG. 13 is SEM photographs showing BIATAINTM available from COLOPLAST
  • FIGS. 14 to 16 are graphs illustrating absorption rate behaviors of polyurethane foam dressings according to production examples (especially, Production Examples 7 to 14) of the present invention.
  • FIG. 17 is a schematic diagram illustrating introduction of a foaming mixture along a fixed and sloped release sheet 3OA according to the present invention.
  • hydrophilic polyurethane as herein used means polyurethane having hydrophilic groups, which exhibits stronger affinity for water than typical polyurethane.
  • moisture permeable film means a polyurethane film with higher moisture permeability than typical polyurethane films manufactured using hydrophilic polyurethane having hydrophilic groups as a raw material.
  • moisture permeable waterproof film means a polyurethane film with moisture permeability as well as water resistance, which is manufactured using hydrophilic polyurethane having hydrophilic groups.
  • the process for manufacturing a polyurethane foam dressing according to the present invention may include the steps of: preparing a polyurethane film layer that is both water permeable and waterproof; preparing a polyurethane prepolymer; preparing a foaming composition; preparing a foaming mixture; regulating a thickness of the foam dressing while laminating a polyurethane foam layer in a tacky gel state on the polyurethane film layer; and carrying out surface modification of the foam layer to increase the absorption rate of the foam layer and/or ageing the polyurethane foam dressing.
  • a moisture permeable waterproof polyurethane resin that is, a polyurethane resin having hydrophilic groups introduced into a main chain which is same as the polyurethane resin used to form the polyurethane foam layer, it is possible to produce a moisture permeable waterproof polyurethane film layer.
  • the polyurethane film layer is duly used to form an outer layer of a dressing manufactured according to the present invention.
  • Isocyanate was introduced into a mixture containing polyol, diol and an antioxidant, followed by reaction therebetween to prepare a polyurethane prepolymer.
  • the polyol used herein is not particularly limited but includes, for example: polypropyleneoxide glycol; polyethyleneoxide glycol; poly tetrame thy lene etherglycol; ethyleneoxide/propyleneoxide copolymer; polytetrahydrofuran/ethyleneoxide copolymer; polytetrahydrofuran/propyleneoxide copolymer; polybutylene carbonate glycol; polyhexame thy lene carbonate glycol; polycaprolactone glycol; polyethylene adipate; polybutylene adipate; polyneopentyl adipate; polyhexamethylene adipate, which may be used alone or as a combination of two or more thereof.
  • the polyurethane prepolymer used to prepare polyurethane foam according to the present invention preferably includes a hydrophilic polyurethane prepolymer having hydrophilic groups. It is well known that ethyleneoxide is a hydrophilic group and ethyleneoxide content is important to make the prepolymer hydrophilic, as described in Journal of Cellular Plastics 1976; 12; 285, Journal of Cellular Plastics 1983; 19; 259, and US Patent No. 4,008,189 (November 4, 1975), which are each hereby incorporated by reference. Most preferable is poljol, especially, an ethyleneoxide/propyleneoxide copolymer having at least two hydroxyl groups, a molecular weight of 500 to 6,000 and an ethyleneoxide content of 20 to 90%.
  • Isocyanate used in the present invention may include aromatic, aliphatic, alicjclic isocyanate and/or mixtures thereof.
  • isocyanate is not particularly limited but includes: 2,4-toluene diisocyanate; 2,6-toluene diisocyanate; methylenedipheyl di- isocyanate; 1,5 -naphthalene diisocyanate; tolidine diisocyanate; hexamethylene- 1,6-diisocyanate; isophorone diisocyanate; xylene diisocyanate; cjclohexylene- 1,4-diisocyanate; lysine diisocyanate; tetramethylene-xylene diisocyanate, which may be used alone or as a combination of two or more thereof.
  • Preferred is the use of isophorone diisocyanate; 2,4-toluene diisocyanate; 2,6-toluene diiso
  • Diol compounds described above are not particularly limited but include, for example: ethylenegljcol; propylenegljcol; 1,3-butandiol; 1,4-butandiol; 1,5-pentandiol; 1,6-hexanediol; trie thy lenegljcol; diethylenegljcol; tetraethyelnegljcol; dipropylenegljcol; dibutylenegljcol; neopentylgljcol; l,4-c ⁇ clohexandimethanol; 24nethyl-l,3-pentandiol, which may be used alone or as a combination of two or more thereof.
  • Preferable is at least one of ethylene glycol, propylene glycol and 1,4-butandiol or a combination of two or more thereof.
  • the diol compound acts as a chain extender for the polyurethane prepolymer so as to increase the molecular weight of the prepolymer and, in addition, increases a content of hard segment, thereby enhancing mechanical properties thereof. IHbwever, if much of the diol compound is added to the prepolymer, the prepolymer exhibits a high viscosity, preventing the prepolymer from being homogeneously mixed with a foaming composition.
  • a prepolymer synthesized with addition of a diol compound preferably has a viscosity of 3,000 to 20,000 cps at 3O 0 C. IHbwever, it is clearly understood that the viscosity of the prepolymer can be easily varied by those skilled in the related art depending on processing conditions including, for example, viscosity of a foaming composition, shape-forming temperature and so on.
  • the additives may include an antioxidant.
  • the antioxidant is not particularly limited but includes, for example: phenyl- beta-naphthalamine; cysteine hydrochloride; dibutylhydroxy toluene; nordihy- droguaiaretic acid; butylhydroxyanisole; phosphoric acid; citric acid; ascorbic acid; erythorbic acid; propyl gallate; and IRGANOX 1010, IRGANOX 1035, IRGANOX 1076, IRGANOX 1330, IRGANOX 1425WL, IRGANOX 3114, IRGANOX B215, IRGANOX B220, IRGANOX B225, IRGANOX B561, IRGANOX B313, IRGANOX B501W, IRGANOX B900
  • More preferable is at least one selected from phosphoric acid, citric acid, dibutylhydroxytoluene, butylhydroxyanisole, IRGANOX 1010, IRGANOX 1035, IRGANOX 1076 and IRGANOX 1330, and/or combinations of two or more thereof.
  • the antioxidant may be added in an amount of 0.05 to 5wt.% with respect to weight of the polyurethane prepolymer.
  • a foaming composition is prepared by mixing water, a cross- linking agent and a surfactant.
  • the foaming composition may comprise 60 to 120 wt. parts of deionized water, 0.5 to 40 wt. parts of a cross-linking agent and 1 to 10 wt. parts of a surfactant. If necessary, the foaming composition may further include 0.01 to 2 wt. parts of a pigment, 0.01 to 20 wt. parts of a drug(s) and 0.1 to 40 wt. parts of a moisturizer and/or an absorption enhancer.
  • the cross-linking agent includes gljcerin, trimethylolpropane, 1,2,4-butane triol and sorbitol, without being limited thereto, which may be used alone or as a combination of two or more thereof.
  • the cross-linking agent functions to improve mechanical properties of the polyurethane foam through cross-linkage during formation of the foam.
  • the surfactant may be applied according to a conventional method and usage of the surfactant is well known in the art.
  • ethyleneoxide/propyleneoxide block copolymers may include F-68, F-87, F-88, F- 108 and F- 127, which are all available from BASF Corp.
  • silicon based surfactants may be exemplified by L-580, L- 603, L-688, L-5420, SZ-1703, L-6900, L-3150, Y-7931, L-1580, L-5340, L-5333, L- 6701, L-5740M, L-3002, L-626, etc.
  • the surfactant may control a size of pores in a wound contact layer 11 and an inner absorptive layer 12 of a polyurethane foam dressing, as well as open porosity of the pores.
  • F-68 as the ethyleneoxide/propyleneoxide block copolymer available from BASF Corp. is well known as the most preferable surfactant that does not damage human tissue, aids in wounds washing, and is non-toxic.
  • the present invention may also use a moisturizer to maintain a moist environment around the wound, thereby substantially inhibiting formation of a hardened scab over the wound while facilitating wound healing.
  • moisturizer as herein used means not only commonly known moisturizers but also wound healing aids that maintain a moist wound environment to inhibit formation of a scab to cover a wound while allowing early wound healing.
  • Such a moisturizer is not particularly limited but includes, for example: propyleneglycol alginate; methylcellulose; sodiun carboxymethylcellulose; calciun carboxymethylcellulose; sodiun carboxymethyl starch; sodiun alginate; arrmoniun alginate; potassiun alginate; calciun alginate; sodiun caseinate; guar gun; locust bean gun; xanthan gun; cyclodextrin; gun Arabic; gellan gun; carrageenan; gun karaya; casein; Tara gun; Tamarind gun; Tragacanth gun; pectin; glucomannan; gun ghatti; arabinogalactan; furcelleran; pullulan; glucosamine; carboxymethyl cellulose; chitin; chitosan; hyaluronic acid; amino acid; L-aspartic acid; sodium L-aspartate; DL-alanine; L-isoleucine;
  • celluloses such as carboxymethyl cellulose may improve mechanical properties of a final product, compared to typical products without the moisturizer.
  • This is substantially considered a "filler," which means a material added to prevent ageing, reinforce performance and/or increase dose of the product in practical uses of rubber or plastic products.
  • the resin alone does not have sufficient strength.
  • many of the conventional technologies have produced resins with reinforced mechanical properties by adding cellulose, asbestos, wood flour, etc.
  • the term "drug” as herein used includes not only typical drugs and antibiotics but also wound healing aids with exhibiting bacteriostasis and promoting proliferation of granulation tissue. Therefore, the drug used in the present invention may also include sugars which are well known to exhibit bacteriostasis and to promote granulation tissue proliferation. Such sugars are not particularly limited but include sucrose, sorbitol, mannitol, fructose, glucose, xylitol, lactose, maltose, maltitol, trehalose, etc.
  • the wound healing aids promoting granulation tissue proliferation may include fibroblast growth factor (FGF), hepatocyte growth factor (FCF), epidermal growth factor (EGF), and so on.
  • FGF fibroblast growth factor
  • FCF hepatocyte growth factor
  • EGF epidermal growth factor
  • the drug may include, especially, natural materials which are well known to exhibit anti- inflammatory, anti-bacterial, anti-fungal and/or skin regeneration effects.
  • Such materials include, for example: bioflavonoids derived from tea tree oil, Sophora An- gustifolia extract, iris extract, Gljcyrrhiza Glabra extract and/or grapefruit seed extract; naringin; polypeptides; tocopherols; asiatic acid derived from Centella Asiatica; and plant derived natural ingredients such as madecasic acid, ⁇ -glucan derived from mushrooms, Neem extract, Witch hazel extract, allantoin, Portulace oleracea extract, Ponciri fructus extract, phytosphingosin, aloe extract and the like.
  • These natural materials may be used alone or as a combination of two or more thereof and added to the foaming composition of the present invention in an amount typically used according to conventional methods within the scope defined above.
  • the foaming composition of the present invention may include silver sulfadiazine, povidone iodide, iodine, ionic iodide, fradiomycin sulfate, acrinol, chlorhexidine, benzalkoniun chloride, benzenetoniun chloride, fucidic acid and salts thereof, etc., in an amount typically used according to conventional methods within the scope defined above.
  • the dressing of the present invention may further include other known drugs for purposes of treatment and/or protection.
  • the foaming composition described above may include an absorption enhancer such as super absorbent polymers commonly used in the art in order to improve absorbability of the polyurethane foam according to the present invention within the scope defined above.
  • an absorption enhancer such as super absorbent polymers commonly used in the art in order to improve absorbability of the polyurethane foam according to the present invention within the scope defined above.
  • the foaming composition of the present invention may include additives with traditionally known effects such as a stabilizing agent, a preservative, a physical property regulator and the like in a small amount for desired purposes thereof.
  • additives with traditionally known effects such as a stabilizing agent, a preservative, a physical property regulator and the like in a small amount for desired purposes thereof.
  • FIG. 17 shows that the foaming mixture is fed over the release sheet 30A fixed at a desired angle "d".
  • the formed foam layer was subjected to a lamination step, preferably, in a tacky gel state before being cured. That is, the polyurethane foam layer was combined with a polyurethane film layer immediately after the foam layer was formed in a tacky gel state on the release sheet. Accordingly, the lamination of the foam layer on the polyurethane film layer was simply achieved without any alternative process using an adhesive agent or a sticking agent, resulting in improved efficiency of the lamination process.
  • the release sheet used in the present invention preferably includes a polymeric film or a paper release sheet, both being surface treated with silicon.
  • the laminated layers were pressed at a constant gap therebetween to control a thickness of a foam dressing.
  • the lamination of the polyurethane foam layer on the polyurethane film layer was simply performed without additional adhesives and/or sticking agents since the polyurethane foam layer was in the tacky gel state before being cured.
  • the lamination process used in the present invention is not particularly limited and may include conventional methods such as use of adhesives or sticking agents, application of pressure, etc.
  • the release sheet was peeled from the film layer.
  • the laminate is often preferably subjected to a following curing step after the hot air drying. This is because the resulting polyurethane foam dressing curls due to shrinkage if the laminate is directly cured in the hot air dryer without the hot air drying step, thereby causing difficulty in winding the foam dressing in a roll form. Another reason is that may inhibit evaporation of moisture remaining in the foam layer. If the moisture is not suitably removed, a wound contact layer of the polyurethane foam dressing has problems of decreased absorption and low absorption rate.
  • a polyurethane foam dressing of the present invention which has only the release sheet in contact with the polyurethane foam layer.
  • the release sheet in contact with the polyurethane foam layer is peeled off when the foam dressing is applied to a patient such that a side of the foam layer having the release sheet peeled off and directly contacts the patient's wound.
  • the polyurethane prepolymer and the foaming composition were agitated at 3,000 rpm to form a foaming mixture, which in turn, was fed over the release sheet fixed at a constant angle. After about 2 minutes, the foaming mixture applied to the release sheet began to form a tacky gel-like polyurethane foam. In this case, bringing a moisture permeable waterproof film in contact with a laminating face of the polyurethane foam layer, (which is the opposite side to the release sheet), to directly form a laminate thereof, followed by drying in a hot air dryer at 100 0 C for 3 minutes.
  • the polyurethane foam dressing obtained from the previous lamination step may further be subjected to an ageing step using the hot air dryer.
  • the release sheet in contact with the film layer was peeled from the polyurethane foam layer.
  • the foam layer was aged in the hot air dryer at 50 to 7O 0 C for a certain period of time.
  • the polyurethane foam dressing shrank some extent and, at the same time, the film layer laminated on an outer side of the polyurethane also shrank to create natural wrinkles.
  • using a specific release sheet with wrinkles such as AR-175 available from Asahi Roll Co., Ltd. may result in similar effects as described above.
  • the ageing process effectively increases mechanical properties of the foam dressing such as tensile strength, modulus of elongation, etc.
  • the moisturizer may include, for example, glycerin, triacetin, propyleneglycol, sorbitol, polyethyleneglycol, etc., which may be used alone or as a combination of two or more thereof.
  • the polyurethane foam is preferably impregnated with a mixture comprising 5 to 20wt. parts of glycerin in lOOwt. parts of 50% ethanol solution.
  • ethanol methanol, isopropyl alcohol and the like may be used, although ethanol is most preferable.
  • the oxygen plasma treatment is suitably conducted for 10 seconds to 2 minutes and, more preferably for 30 to 60 seconds.
  • Surface modification may be accomplished by any one selected from the use of moisturizer and the oxygen plasma treatment and/or a combination thereof such that the oxygen plasma treatment is carried out after moisturizing the polyurethane foam.
  • the combined treatment is more preferable in view of surface modification effects.
  • the surface modification is preferably carried out after completion of the manufacture of foam dressing through the steps described above, however, the present invention is not limited thereto. If necessary, the surface modification may be performed in any one of following steps after preparing a foam layer.
  • the polyurethane foam was fixed on a sample fixing part.
  • a rotary vane vacuum punp was used to apply a vacuun to a reactor.
  • a flow rate controller controlled the internal pressure of the reactor by oxygen injection. After the reactor pressure was set to 250 mTorr, oxygen was injected to the reactor for 10 minutes to generate oxygen plasma for 30 to 60 seconds, which in turn, was used to treat a surface of the polyurethane foam.
  • FIGS. 14 to 16 are graphs illustrating absorption rate behaviors of the polyurethane foam dressing according to the present invention. As shown in the graphs, saturated absorption of the foam dressing is proportional to oxygen plasma treatment time. Also, a foam dressing treated with oxygen plasma after impregnating the dressing with a moisturizer such as glycerin and drying, exhibited shorter time reaching the saturated absorption than that of a foam dressing prepared without a pre-treatment using the moisturizer. From FIG. 16, it was found that, even without the oxygen plasma treatment, concentration of glycerin in a solution for impregnation of a dressing is proportional to the saturated absorption.
  • the polyurethane foam dressing of the present invention manufactured by the previous process includes a foam layer comprising polyurethane foam and a polyurethane film layer, wherein the foam layer is divided into two layers.
  • a foam layer comprising polyurethane foam and a polyurethane film layer, wherein the foam layer is divided into two layers.
  • FIGS. 1 to 4 are schematic views illustrating a polyurethane foam dressing according to an exemplary embodiment of the present invention.
  • FIG. 1 is a schematic cross- sectional view showing the polyurethane foam dressing, which comprises a foam layer 10 and an outer film layer 20 made of waterproof polyurethane.
  • the foam layer 10 is characterized by a bilayer structure that includes a skin contact layer 11 having microfine open cells with a diameter of 1 to 50/M and an internal absorptive layer 12 having a nunber of open cells with a diameter of 1 to 1,000/M.
  • the open cell has numerous pores perforating the open cell. Each of the pores has an average diameter of 1 to 50/M.
  • FIG. 2 is a schematic view showing the polyurethane film layer 20.
  • This layer is formed by defoaming polyurethane resin using a vacuun agitation defoaming device to remove air bubbles, applying the defoamed resin to a matt release sheet 30B, and drying the coated sheet.
  • the polyurethane resin used in this case may include moisture permeable waterproof polyurethane resin having at least one hydrophilic group in a main chain, which is substantially identical to polyurethane resin used in preparing the polyurethane foam layer, thereby producing a polyurethane film layer that is both moisture permeable and waterproof.
  • FIG. 3 is a schematic view showing a polyurethane foam layer 10.
  • the polyurethane foam layer 10 is prepared by mixing a polyurethane prepolymer and a foaming composition, stirring the mixture at a high speed and feeding the homogeneous mixture over a silicon treated release sheet 30A fixed at a certain angle such that the mixture is foamed while flowing over an inclined face of the release sheet.
  • the foam layer is divided into two layers 11 and 12 naturally formed due to difference in pore conditions, by mixing the polyurethane prepolymer and a foaming composition and allowing the mixture to come into direct contact with the release sheet 3OA to form a skin layer.
  • the mixture forms finer open cells in a region in contact with the release sheet 30A than in a region in contact with the skin layer.
  • the contact region with finer open cells is called 'a wound contact layer 11' while another region with a nunber of larger open cells is 'an absorptive layer 12.
  • the absorptive layer 12 mainly serves to absorb wound exudates in the polyurethane foam dressing.
  • FIG. 4 is a schematic view showing a polyurethane foam dressing to which a release sheet is attached.
  • the release sheet 30B attached to a film layer 20 is peeled off during production of the foam dressing while another release sheet 30A adhered to a foam layer 10 is removed immediately before using the foam dressing.
  • the wound contact layer 11 which has microfine open cells with a diameter of 1 to 50/M, absorbs wound exudates while not adhering to the wound.
  • the absorptive layer 12 at an inner side of the foam dressing which has a plurality of open cells with a diameter of 1 to 1,000/M, can absorb and hold 100 to l,000wt.% of liquid fractions therein and has a density of 0.1 to 0.8g/cnf . Both of the open cells have pores that perforate the open cells and have an average diameter of 1 to 50/M.
  • the film layer as a moisture permeable waterproof film at an outer side of the foam dressing has high moisture permeability of 400 to 3,000g/m7day (with relative humidity of 10 to 90% at 3TC as determined by the Desiccant Method), inhibits invasion of bacteria and/or viruses from the outside, prevents exudates from leaking from the dressing, and forms a moist environment around the wound.
  • FIGS. 1 to 4 are only given for illustration of the polyurethane foam dressing according to the present invention and the foam dressing of the present invention can be manufactured in various dimensions and/or morphologies according to uses and requirements thereof.
  • Each of the polyurethane foam dressings produced in the previous production examples was subjected to oxygen plasma treatment using a plasma reactor Model EPPS 2000 available from PLASMART Inc. for 30 seconds and 60 seconds, respectively.
  • the oxygen plasma treatment was performed at a pressure of 250 mTorr.
  • an internal pressure of the reactor was measured using a vacuum gauge Model 801 (Varian) while a flow rate of fluid was determined using a mass flow controller MFC (Brooks, Japan, Model 5850E). Observation of color plasma lights in the reactor resulted in determination of stable plasma generation.
  • Table 4 also includes times required for the oxygen plasma treatment of the polyurethane foam dressings prepared in the previous production examples.
  • a sample of the foam dressing was prepared with a size of 3cmx3cm and left at room temperature for 24 hours. Then, after dipping and storing the sample in distilled water at 3TC, the sample was subjected to measurement to determine time when the weight of the sample no longer increased.
  • thermohydrostat SH- CTH 150 available from SAMHEUNG INSTRUMENT according to ASTM E 96-94 (desiccant method).
  • the thermohydrostat had a temperature of 37C+2 and a relative humidity of 80%+5.
  • the absorption equilibriun time was 70 sec, which is considerably shorter than that of the foam dressing without the oxygen plasma treatment in Production Example 7.
  • the foam dressings manufactured in Production Examples 11 and 12 which moisturize the foam dressing in a mixture comprising 5 wt. parts of gljcerin in 100 wt. parts of 50% ethanol solution and then, perform the oxygen plasma treatment, exhibited reduced absorption equilibrium times of 70 sec and 60 sec, respectively.
  • the foam dressings manufactured in Production Examples 13 and 14 including only a pre-treatment that impregnates the foam dressing with a high concentration moisturizer such as gljcerin and dries the impregnated foam dressing, without the oxygen plasma treatment, also exhibited greatly reduced times required to reach saturated absorption. Therefore, it is understood that time taken to reach saturated absorption can be appropriately controlled by regulating the duration of oxygen plasma treatment and/or the concentration of moisturizer, or by impregnating the foam dressing with the moisturizer.
  • the foam dressing manufactured by pressing a thickness control gap many times to cause a decrease in sizes of open cells and a reduction in nunber of pores perforating the open cells shows reduced saturated absorption rate.
  • IHbwever referring to Production Example 18, 19 and 20, it is confirmed that the oxygen plasma treatment and/or the pre-treatment using a moisturizer can preferably improve the saturated absorption rate of the foam dressing.
  • the sizes of the open cells and pores are substantially reduced while increasing a density of foam materials in the foam dressing, resulting in improved physical properties of the foam dressing.
  • mechanical properties of a polyurethane foam dressing can be controlled by various parameters such as addition of a chain extender, a content of hard segment, addition of a cross-linking agent and/or powdery additive such as carboxylmethyl cellulose, control of gap in a thickness control part of the foam dressing, etc. and, in addition, a polyurethane foam dressing with different physical properties and other features can be manufactured by adopting an oxygen plasma treatment and/or using a moisturizer.
  • FIGS. 5 to 8 are SEM photographs showing polyurethane foam dressings of the present invention, in particular, FIGS. 5, 6, 7 and 8 illustrate SEM photographs of the polyurethane foam dressings manufactured in Production Examples 15, 16, 17 and 21, respectively.
  • a in the figures represents an internal absorptive layer 12, while B represents a wound contact layer 11.
  • the internal absorptive layer is larger than the wound contact layer.
  • the internal absorptive layer has larger and more open cells and pores perforating the open cells than those in the wound contact layer.
  • FIG. 9 is SEM photographs showing a polyurethane foam dressing, MEDIFOAM-N
  • FIG. 10 is SEM photographs showing another polyurethane foam dressing
  • MEDIFOAM-F available from IL DONG Pharmaceutical Co., LTD. (LOT. 02F01007, Date of manufacture: April 5, 2007, Korea). This is manufactured by preparing a block form dressing using a mold and removing a skin layer from the dressing using a horizontal cutter.
  • the foam dressing includes an internal absorptive layer and a wound contact layer which have substantially the same structure. If there are too many open cells in the wound contact layer and/or the open cells are too large, although the foam dressing can have large open cells on a skin facing side, thus improving absorption rate of wound exudates, the skin facing side may adhere to epithelial tissue regenerated at or around a wound site, thus, cause a problem of pain or secondary damage during removal of the dressing.
  • FIG. 11 is SEM photographs showing another polyurethane foam dressing
  • ALLEVYNTM available from SMITH & NEPHEW (LOT. 0611 60229, Date of manufacture: March 13, 2006, United Kingdom). Similar to other conventional products, this dressing has open cells and perforated pores through the open cells and the open cells are somewhat large. Also, "B" as a wound contact layer has at least one skin layer S formed by laminating polymer films in a net form.
  • FIG. 12 is SEM photographs showing another polyurethane foam dressing
  • FIG. 13 is SEM photographs showing another polyurethane foam dressing
  • This dressing has an internal absorptive layer with a structure similar to that of the dressing shown in FIG. 8. Fbwever, a wound contact layer of the dressing has a nunber of open cells containing a few skin layers S.
  • the polyurethane foam dressing manufactured according to the present invention has different morphologies.
  • the present invention can provide a variety of polyurethane foam dressings with appropriate structure and absorption rate depending on states and conditions of various wounds. If necessary, hydrophilic properties of the polyurethane foam dressing may be controlled by surface modification such as pre-treatment using a moisturizer, oxygen plasma treatment, etc.
  • a method comprising: mixing a hydrophilic polyurethane prepolymer, deionized water, a surfactant and/or a cross- linking agent under stirring at high speed to prepare a foaming mixture; feeding the foaming mixture over a silicon release sheet fixed at a certain angle such that the foaming mixture is foamed while flowing over an inclined surface of the release sheet; and laminating the resulting polyurethane foam layer in a tacky gel state on a moisture permeable waterproof polyurethane film layer then pressing the laminated foam dressing while maintaining a certain gap therebetween to regulate a thickness of the foam dressing.
  • the method of the present invention has advantages such as noticeably improved productivity and processing efficiency.
  • the method of the present invention allows mass production of foam dressings as 'pot life' is unlimited, thereby considerably reducing production costs and enabling sufficient supply of low cost foam dressings with improved physical properties.
  • the resulting foam is subjected to oxygen plasma treatment to improve absorption rate thereof, thereby producing a polyurethane foam dressing with enhanced performance. Also, controlling conditions for surface modification such as a time required for oxygen plasma treatment, concentration of the moisturizer and/or depending on whether the foam dressing is impregnated with the moisturizer or not, it is possible to manufacture a variety of foam dressings with appropriate absorption rates depending on conditions and states of various wounds.
  • the present invention can considerably improve productivity of foam dressings by adopting novel and efficient processes and also provide a polyurethane foam dressing that has superior physical properties to expensive foam dressings manufactured by conventional methods and is capable of being easily formed in various shapes and different sizes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un procédé de production d'un pansement en mousse de polyuréthane qui protège les blessures, telles que les plaies ou les brûlures, et se révèle utile dans la cicatrisation. Plus particulièrement, la présente invention concerne un procédé de fabrication d'un pansement en mousse de polyuréthane dont la productivité et l'efficacité de traitement sont remarquablement améliorées. Ce procédé, qui permet d'améliorer les propriétés physiques du pansement en mousse de polyuréthane, comprend les étapes suivantes : préparation d'une couche d'une pellicule de polyuréthane imperméable perméable à l'humidité ; préparation d'un prépolymère de polyuréthane ; préparation d'un mélange de moussage de polyuréthane ; obtention d'une couche de mousse de polyuréthane de type gel poisseux ; application d'une couche de mousse de polyuréthane de type gel poisseux sur la couche de pellicule de polyuréthane ; et enroulement du pansement en mousse de polyuréthane ainsi produit sous la forme d'un rouleau, puis vieillissement du pansement de mousse. Le procédé inclut en outre l'imprégnation de la mousse de polyuréthane avec un hydratant et le séchage de ladite mousse, puis le traitement de cette mousse avec du plasma d'oxygène afin de modifier une surface du pansement de mousse et d'améliorer par là même le taux d'absorption dudit pansement. Le procédé de cette invention présente des avantages, tels qu'une productivité et une efficacité de traitement remarquablement améliorées, permettant ainsi la production en masse de pansements en mousse. Ainsi, il est possible de réduire considérablement les coûts de production et de fournir à bas prix des pansements en mousse présentant des propriétés physiques améliorées.
PCT/KR2008/003414 2007-06-21 2008-06-17 Procédé de production d'un pansement en mousse hydrophile et pansement en mousse hydrophile ainsi produit WO2008156285A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008800211005A CN101730515B (zh) 2007-06-21 2008-06-17 一种聚氨酯泡沫敷料制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2007-0061239 2007-06-21
KR20070061239 2007-06-21
KR10-2008-0018998 2008-02-29
KR1020080018998A KR100937816B1 (ko) 2007-06-21 2008-02-29 친수성 폼 드레싱재의 제조방법 및 제조된 친수성 폼드레싱재

Publications (1)

Publication Number Publication Date
WO2008156285A1 true WO2008156285A1 (fr) 2008-12-24

Family

ID=40156394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/003414 WO2008156285A1 (fr) 2007-06-21 2008-06-17 Procédé de production d'un pansement en mousse hydrophile et pansement en mousse hydrophile ainsi produit

Country Status (1)

Country Link
WO (1) WO2008156285A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596560A (zh) * 2010-11-09 2014-02-19 张洁 薄层和液体结合的透皮给药***
CN104225665A (zh) * 2014-09-30 2014-12-24 南阳市汇博生物技术有限公司 一种有机聚氨酯泡沫敷料及其制备方法
CN104667334A (zh) * 2015-03-24 2015-06-03 深圳市源兴纳米医药科技有限公司 一种含复合银锌抗菌材料的泡沫敷料及其制备方法
CN105497963A (zh) * 2015-12-28 2016-04-20 王书美 外伤止血用聚氨酯敷料及制备方法
WO2018149835A1 (fr) * 2017-02-16 2018-08-23 Covestro Deutschland Ag Procédé pour la préparation d'un matériau composite pour le contact avec une plaie, exempt de substance adhésive
JP2018525102A (ja) * 2015-08-12 2018-09-06 ジェネウェル シーオー．，エルティーディー． 抗菌ドレッシング材及びその製造方法
CN109125784A (zh) * 2018-10-08 2019-01-04 振德医疗用品股份有限公司 一种亲水聚氨酯泡沫敷料及其制造方法
CN111067710A (zh) * 2019-12-25 2020-04-28 湖州斯蔓生物材料有限公司 医用敷料的制备方法及其制得的医用敷料以及急救包
JP2021505278A (ja) * 2017-12-08 2021-02-18 エシティ・ハイジーン・アンド・ヘルス・アクチエボラグ 吸収性物品及び吸収性物品の製造方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961629A (en) * 1968-06-11 1976-06-08 American Cyanamid Company Using hydrophilic polyurethane laparotomy sponges
US5849368A (en) * 1995-02-01 1998-12-15 Schneider (Usa) Inc Process for hydrophilicization of hydrophobic polymers
US6120904A (en) * 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
KR100340981B1 (ko) * 1999-07-01 2002-06-20 박명환 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법
US20040018227A1 (en) * 2002-06-28 2004-01-29 Myung-Hwan Park Multilayered microporous foam dressing and method for manufacturing the same
KR100553078B1 (ko) * 2003-12-18 2006-02-15 주식회사 바이오폴 2층 구조의 친수성 폴리우레탄 폼 드레싱재
US20060079589A1 (en) * 2002-12-27 2006-04-13 Kahei Co., Ltd. Polyurethane foam sheet and process for layered sheet with the same
JP2007097844A (ja) * 2005-10-05 2007-04-19 Hideki Aoki 生体用高分子材料
KR100716658B1 (ko) * 2005-11-11 2007-05-09 주식회사 원바이오젠 폴리우레탄 폼 드레싱재의 제조방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3961629A (en) * 1968-06-11 1976-06-08 American Cyanamid Company Using hydrophilic polyurethane laparotomy sponges
US5849368A (en) * 1995-02-01 1998-12-15 Schneider (Usa) Inc Process for hydrophilicization of hydrophobic polymers
US6120904A (en) * 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
KR100340981B1 (ko) * 1999-07-01 2002-06-20 박명환 친수성 폴리우레탄 폼 드레싱재 및 그 제조 방법
US20040018227A1 (en) * 2002-06-28 2004-01-29 Myung-Hwan Park Multilayered microporous foam dressing and method for manufacturing the same
US20060079589A1 (en) * 2002-12-27 2006-04-13 Kahei Co., Ltd. Polyurethane foam sheet and process for layered sheet with the same
KR100553078B1 (ko) * 2003-12-18 2006-02-15 주식회사 바이오폴 2층 구조의 친수성 폴리우레탄 폼 드레싱재
JP2007097844A (ja) * 2005-10-05 2007-04-19 Hideki Aoki 生体用高分子材料
KR100716658B1 (ko) * 2005-11-11 2007-05-09 주식회사 원바이오젠 폴리우레탄 폼 드레싱재의 제조방법

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109444B (zh) * 2010-11-09 2019-12-13 张洁 薄层和液体结合的透皮给药***
WO2012064766A3 (fr) * 2010-11-09 2014-04-17 Jie Zhang Systèmes de combinaison d'un feuillet et d'un liquide destinés à administrer des médicaments par voie percutanée
CN103596560B (zh) * 2010-11-09 2016-08-10 张洁 薄层和液体结合的透皮给药***
CN106109444A (zh) * 2010-11-09 2016-11-16 张洁 薄层和液体结合的透皮给药***
CN103596560A (zh) * 2010-11-09 2014-02-19 张洁 薄层和液体结合的透皮给药***
CN104225665A (zh) * 2014-09-30 2014-12-24 南阳市汇博生物技术有限公司 一种有机聚氨酯泡沫敷料及其制备方法
CN104225665B (zh) * 2014-09-30 2015-12-09 南阳市汇博生物技术有限公司 一种有机聚氨酯泡沫敷料及其制备方法
CN104667334A (zh) * 2015-03-24 2015-06-03 深圳市源兴纳米医药科技有限公司 一种含复合银锌抗菌材料的泡沫敷料及其制备方法
JP2018525102A (ja) * 2015-08-12 2018-09-06 ジェネウェル シーオー．，エルティーディー． 抗菌ドレッシング材及びその製造方法
CN105497963A (zh) * 2015-12-28 2016-04-20 王书美 外伤止血用聚氨酯敷料及制备方法
WO2018149835A1 (fr) * 2017-02-16 2018-08-23 Covestro Deutschland Ag Procédé pour la préparation d'un matériau composite pour le contact avec une plaie, exempt de substance adhésive
US11730853B2 (en) 2017-02-16 2023-08-22 Covestro Intellectual Property Gmbh & Co. Kg Method for producing an adhesive-free wound contact composite material
JP2021505278A (ja) * 2017-12-08 2021-02-18 エシティ・ハイジーン・アンド・ヘルス・アクチエボラグ 吸収性物品及び吸収性物品の製造方法
CN109125784A (zh) * 2018-10-08 2019-01-04 振德医疗用品股份有限公司 一种亲水聚氨酯泡沫敷料及其制造方法
CN109125784B (zh) * 2018-10-08 2023-08-04 振德医疗用品股份有限公司 一种亲水聚氨酯泡沫敷料及其制造方法
CN111067710A (zh) * 2019-12-25 2020-04-28 湖州斯蔓生物材料有限公司 医用敷料的制备方法及其制得的医用敷料以及急救包

Similar Documents

Publication Publication Date Title
KR100985969B1 (ko) 친수성 폼 드레싱재의 제조방법 및 제조된 친수성 폼 드레싱재
WO2008156285A1 (fr) Procédé de production d'un pansement en mousse hydrophile et pansement en mousse hydrophile ainsi produit
KR100745050B1 (ko) 폴리우레탄 폼 드레싱재의 제조방법 및 제조장치
JP6705888B2 (ja) 抗菌ドレッシング材及びその製造方法
CN114795657B (zh) 伤口处理中的复合泡沫
KR101199453B1 (ko) 폴리우레탄 폼 드레싱재의 연속 제조방법 및 장치
KR101202875B1 (ko) 메쉬 필름을 포함하는 친수성 폴리우레탄 폼 드레싱재 및 그의 제조방법
KR100780846B1 (ko) 약물함유층을 갖는 폴리우레탄 폼 드레싱재 및 그의제조방법
EP1374812A1 (fr) Pansement de mousse microporeux multi-couche et son procédé de fabrication
CN110753536B (zh) 聚氨酯泡沫面膜材料及其制备方法
CA2648368A1 (fr) Articles moussants biomedicaux
KR101022884B1 (ko) 약물층을 포함하는 폴리우레탄 폼 드레싱제 및 그 제조방법
KR200422370Y1 (ko) 창상피복재
KR100832009B1 (ko) 미세다공성 폼층을 가진 반창고용 필름 및 그 제조 방법
KR102253879B1 (ko) 은-활성탄 복합체를 함유하는 폴리우레탄 폼 드레싱재 및 그 제조방법
KR100716658B1 (ko) 폴리우레탄 폼 드레싱재의 제조방법
KR101811273B1 (ko) 개선된 폴리우레탄 마스크 팩재 및 그의 제조 방법
JP5417571B2 (ja) 創傷被覆材
KR101933486B1 (ko) 항균성 폴리우레탄 폼 드레싱재 및 이의 제조방법
CA2027894C (fr) Procede pour la preparation d'une feuille en mousse de polymere
WO2005065604A1 (fr) Pansement
JP2001340375A (ja) 創傷被覆材
KR100667292B1 (ko) 창상피복용 드레싱재
KR20090034173A (ko) 실크 드레싱재
KR102426702B1 (ko) 히알루론산염 망사 필름 및 이의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880021100.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08766376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08766376

Country of ref document: EP

Kind code of ref document: A1